Groupe SynerLAB
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Groupe SynerLAB - overview
Established
2001
Location
-, -, France
Primary Industry
Pharmaceuticals
About
Based in France, Groupe SynerLAB is a Contract Development and Manufacturing Organization (CDMO) that focuses on providing comprehensive services in the pharmaceutical industry, including development and production of various dosage forms. Groupe SynerLAB operates as a CDMO, specializing in pharmaceutical development and manufacturing. Founded in 2001 and headquartered in France, the company has evolved its strategies to meet the needs of pharmaceutical clients. The current CEOs are Danny C and Juan García.
They recently secured a BUYOUT funding round of USD 100. 00 mn from investors including 21 Invest and Ardian, bringing their total raised amount to USD 100. 00 mn. The most recent deal occurred on September 25, 2024.
Groupe SynerLAB provides a range of services as a comprehensive CDMO, including the development and manufacturing of sterile and non-sterile lyophilized products, oral solids, semi-solids, and liquid formulations. Their end-to-end services cover formulation development, manufacturing, packaging, and regulatory affairs, catering primarily to pharmaceutical companies that require support in launching complex medicinal products. In the most recent year, 2020, Groupe SynerLAB generated a revenue of USD 6,616,789. 70 and reported an EBITDA of USD 1,159,328.
The revenue is primarily derived from business-to-business transactions with pharmaceutical manufacturers and developers seeking specialized CDMO services, structured through customized agreements. In September 2024, Blue Wolf Capital Partners agreed to acquire Groupe SynerLAB, indicating a significant step in its growth strategy. The company plans to leverage recent funding to expand its capabilities and penetrate new markets, specifically targeting European regions for growth while enhancing its product offerings to meet evolving client needs.
Current Investors
Ardian, 21 Invest
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.synerlab.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Groupe SynerLAB - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Secondary Buyout | Completed | Groupe SynerLAB | - | ||||||||
| Add-on | Completed | Laboratorios Alcala Farma S.L. | - | ||||||||
| Secondary Buyout | Completed | Groupe SynerLAB | - | ||||||||
| Add-on | Completed | Lyofal | - | ||||||||
| Add-on | Completed | IDD Tech Orleans | - |
Displaying 1 - 5 of 7
Groupe SynerLAB - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| President Supervisory Board | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.